SOLO - Pharmaco-Imaging | Preclinical Imaging Services | Oncodesign

Pharmaco-Imaging

Non-invasive studies to support proof of concept in pharmacology

Imaging is a non-invasive tool for pharmacology enabling to significantly reduce the number of animals and to efficiently monitor:

  • the biodistribution of drugs.
  • the expression and engagement of in vivo targets.
  • the effect of therapeutic treatments.
  • their mechanism of action.
  • their pharmacodynamic.
Pharmaco-Imaging Studies in Drug Discovery | Oncodesign
Preclinical Imaging Services | Multimodal technologies to understand the pharmacology

Oncodesign Services has added imaging to its pharmacology platform in 2004, integrating along the years multimodalities:

  • MRI 4.7T
  • Nuclear imaging (PET/CT, SPECT/CT, PET/MR)
  • Optical imaging (Bioluminescence, Fluorescence)
  • Ultrasound

 

Oncodesign Services’ in vivo multi-modal imaging platform can be used for biodistribution studies, tumor tracking and to detect biomarkers of activity. Pharmaco-imaging studies often work with radioisotopes, leveraging the capabilities of our bioconjugation and radiochemistry capabilities. It is applicable to small molecules, biologics, nanoparticles.

Pharmimage® – a non-invasive pharmaco-imaging capability

Our technology module, Pharmimage® is designed to monitor the effect of treatments and to define effective translational biomarkers in precision medicine. It helps to answer questions using noninvasive, wholebody techniques:

  • Is the target expressed? (Diagnosis of the disease, heterogeneity of target expression, distribution of the target in metastatic cancer, CNS, cardiology, etc.)
  • Does the drug reach the target? (Pharmacokinetics, biodistribution, bloodbrain barrier crossing, etc.)
  • Is the target inhibited/activated, and does this induce biochemical and biological changes? (Pharmacodynamics, immunomonitoring, optimal biological dose, etc.)
  • Are there any potential toxicities and drug interactions? (Safety, study on drug combinations, metabolism, etc.)
  • Are these changes related to a clinical criterion? (Efficacy of a new treatment, monitoring of the immune response to a vaccine, emergence of resistance in precision medicine, etc.)
  • Can subpopulations of responders be determined? (Translational biomarker)